• Something wrong with this record ?

Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists

P. Baji, L. Gulácsi, BD. Lovász, PA. Golovics, V. Brodszky, M. Péntek, F. Rencz, PL. Lakatos,

. 2016 ; 51 (1) : 22-7. [pub] 20150610

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

OBJECTIVE: To explore preferences of gastroenterologists for biosimilar drugs in Crohn's disease. MATERIAL AND METHODS: Discrete choice experiment was carried out involving 51 Hungarian gastroenterologists in May 2014. The following attributes were used to describe hypothetical choice sets: 1) type of the treatment (biosimilar/originator), 2) severity of disease, 3) availability of continuous medicine supply, 4) frequency of the efficacy check-ups. Multinomial logit model was used to differentiate between three attitude types: 1) always opting for the originator, 2) willing to consider biosimilar for biological-naïve patients only, 3) willing to consider biosimilar treatment for both types of patients. Conditional logit model was used to estimate the probabilities of choosing a given profile. RESULTS: Men, senior consultants, working in inflammatory bowel disease center and treating more patients were more likely willing to consider biosimilar for biological-naïve patients only. Treatment type (originator/biosimilar) was the most important determinant of choice for patients already treated with biologicals, and the availability of continuous medicine supply in case of biological-naïve patients. The probabilities of choosing the biosimilar with all the benefits offered over the originator under current reimbursement conditions are 89% versus 11% for new patients, and 44% versus 56% for patients already treated with biological. CONCLUSIONS: For gastroenterologist, the continuous medical supply would be one of the major benefits of biosimilars. However, benefits offered in the scenarios do not compensate for the change from the originator to the biosimilar treatment of patients already treated with biologicals.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16028418
003      
CZ-PrNML
005      
20161031122952.0
007      
ta
008      
161005s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.3109/00365521.2015.1054422 $2 doi
024    7_
$a 10.3109/00365521.2015.1054422 $2 doi
035    __
$a (PubMed)26059967
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Baji, Petra $u a 1 Department of Health Economics, Corvinus University of Budapest , Fővám tér 8, H-1093 Budapest, Hungary, Europe. b 2 CERGE-EI Fellow, Politických vězňů 936/7 , 110 00 Praha 1-Nové Město, The Czech Republic, Europe.
245    10
$a Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists / $c P. Baji, L. Gulácsi, BD. Lovász, PA. Golovics, V. Brodszky, M. Péntek, F. Rencz, PL. Lakatos,
520    9_
$a OBJECTIVE: To explore preferences of gastroenterologists for biosimilar drugs in Crohn's disease. MATERIAL AND METHODS: Discrete choice experiment was carried out involving 51 Hungarian gastroenterologists in May 2014. The following attributes were used to describe hypothetical choice sets: 1) type of the treatment (biosimilar/originator), 2) severity of disease, 3) availability of continuous medicine supply, 4) frequency of the efficacy check-ups. Multinomial logit model was used to differentiate between three attitude types: 1) always opting for the originator, 2) willing to consider biosimilar for biological-naïve patients only, 3) willing to consider biosimilar treatment for both types of patients. Conditional logit model was used to estimate the probabilities of choosing a given profile. RESULTS: Men, senior consultants, working in inflammatory bowel disease center and treating more patients were more likely willing to consider biosimilar for biological-naïve patients only. Treatment type (originator/biosimilar) was the most important determinant of choice for patients already treated with biologicals, and the availability of continuous medicine supply in case of biological-naïve patients. The probabilities of choosing the biosimilar with all the benefits offered over the originator under current reimbursement conditions are 89% versus 11% for new patients, and 44% versus 56% for patients already treated with biological. CONCLUSIONS: For gastroenterologist, the continuous medical supply would be one of the major benefits of biosimilars. However, benefits offered in the scenarios do not compensate for the change from the originator to the biosimilar treatment of patients already treated with biologicals.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x ekonomika $x terapeutické užití $7 D000911
650    _2
$a biosimilární léčivé přípravky $x ekonomika $x terapeutické užití $7 D059451
650    12
$a výběrové chování $7 D002755
650    _2
$a Crohnova nemoc $x farmakoterapie $x ekonomika $7 D003424
650    _2
$a ženské pohlaví $7 D005260
650    12
$a zdraví - znalosti, postoje, praxe $7 D007722
650    _2
$a lidé $7 D006801
650    _2
$a infliximab $x ekonomika $x terapeutické užití $7 D000069285
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lékaři $7 D010820
650    _2
$a lékařská praxe - způsoby provádění $x statistika a číselné údaje $7 D010818
650    _2
$a průzkumy a dotazníky $7 D011795
651    _2
$a Maďarsko $7 D006814
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Gulácsi, László $u a 1 Department of Health Economics, Corvinus University of Budapest , Fővám tér 8, H-1093 Budapest, Hungary, Europe.
700    1_
$a Lovász, Barbara D $u c 3 1st Department of Medicine, Semmelweis University, Korányi Sándor utca 2a , H-1083 Budapest, Hungary, Europe.
700    1_
$a Golovics, Petra A $u c 3 1st Department of Medicine, Semmelweis University, Korányi Sándor utca 2a , H-1083 Budapest, Hungary, Europe.
700    1_
$a Brodszky, Valentin $u a 1 Department of Health Economics, Corvinus University of Budapest , Fővám tér 8, H-1093 Budapest, Hungary, Europe.
700    1_
$a Péntek, Márta $u a 1 Department of Health Economics, Corvinus University of Budapest , Fővám tér 8, H-1093 Budapest, Hungary, Europe. d 4 Department of Rheumatology, Flór Ferenc County Hospital , Semmelweis tér 1, H-2143 Kistarcsa, Hungary, Europe.
700    1_
$a Rencz, Fanni $u a 1 Department of Health Economics, Corvinus University of Budapest , Fővám tér 8, H-1093 Budapest, Hungary, Europe. e 5 Semmelweis University Doctoral School of Clinical Medicine , Üllői út 26, H-1085 Budapest, Hungary, Europe.
700    1_
$a Lakatos, Péter L $u c 3 1st Department of Medicine, Semmelweis University, Korányi Sándor utca 2a , H-1083 Budapest, Hungary, Europe.
773    0_
$w MED00010598 $t Scandinavian journal of gastroenterology $x 1502-7708 $g Roč. 51, č. 1 (2016), s. 22-7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26059967 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161031122916 $b ABA008
999    __
$a ok $b bmc $g 1166732 $s 953048
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 51 $c 1 $d 22-7 $e 20150610 $i 1502-7708 $m Scandinavian journal of gastroenterology $n Scand J Gastroenterol $x MED00010598
LZP    __
$a Pubmed-20161005

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...